Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 crore The company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to BSE.
Select mid & smallcap stocks can provide the necessary alpha: Sacchitanand Uttekar We expect markets to remain choppy throughout the week. Most of the price based evidence is pointing towards a broad range action within 11250-11750 with 11550 as its breakeven zone.
Reopening of economy, increased testing, no mask use led to rise in COVID-19 cases in Delhi: Experts The national capital has reported coronavirus cases in excess of 2,000 for four consecutive days since September 1. On Friday, the daily cases count stood at 2,914.